Endoscopic submucosal dissection (ESD) has become the gold standard for endoscopic treatment of superficial gastrointestinal neoplasms [1, 2]. However, the procedure requires advanced training and is associated with a risk of adverse events (AEs) [3]. Endosurgical devices with injection function have been reported to decrease operation time for experts [4]. However, non-experts require longer procedure times and have a higher risk of AEs [5], and therefore evaluation of the efficacy of use of these devices by non-experts may be clinically important.

In collaboration with Pentax Medical, HOYA Corporation, we have developed a second-generation endosurgical knife (DN-D2618B; HOYA Corporation, Pentax, Tokyo, Japan), and previously performed an animal feasibility study on the efficacy of this prototype [6]. The aim of this prospective pilot clinical feasibility study was to evaluate the efficacy of clinical ESD using this novel knife.

In collaboration with Pentax Medical, HOYA Corporation, we have developed a second-generation endosurgical knife (DN-D2718B; HOYA Corporation, Pentax, Tokyo, Japan), and previously performed an animal feasibility study on the efficacy of this prototype [6]. The aim of this prospective pilot clinical feasibility study was to evaluate the feasibility of ESD using a novel ESD knife (DN-D2718B).

**Background and study aims** Endoscopic devices with injection function have been reported to decrease endoscopic submucosal dissection (ESD) operation times for experts, but the efficacy of these devices for inexperienced endoscopists is unclear. The aim of this study was to evaluate the feasibility of ESD using a novel ESD knife (DN-D2718B).

**Patients and methods** This is a single-center prospective pilot clinical feasibility study. Patients diagnosed with superficial gastrointestinal neoplasms were enrolled. A pre-specified group of ESD trainees with ESD experience on a porcine gastric model and fewer than 30 cases of ESD in their selected fields performed ESD under expert supervision, using the DN-D2718B. En bloc resection rates, R0 resection rates, procedure times, and incidence of intra-operative/post-operative adverse events were assessed.

**Results** Between June 2015 and January 2016, 13 esophageal, 27 gastric, and 14 colorectal ESD cases were performed per-protocol with mean resection speeds of 10.2, 12.0, and 15.5 mm²/min, respectively. There were no intra-operative/post-operative adverse events.

**Conclusion** ESD with this novel knife is feasible even when performed by non-experts.

---

**Authors**
Yoshiki Sakaguchi¹, Yosuke Tsuji¹, Mitsuhiro Fujishiro¹-², Yosuke Kataoka¹, Itaru Saito¹, Satoki Shichijo¹, Chihiro Minatsuki¹, Itsuko Asada-Hirayama¹, Daisuke Yamaguchi², Keiko Niimi³, Satoshi Ono¹, Shinya Kodashima¹, Nobutake Yamamichi¹, Kazuhiko Koike¹

**Institutions**
1 Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
2 Department of Endoscopy and Endoscopic Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
3 Center for Epidemiology and Preventive Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan

**Submitted** 21.9.2016
**Accepted after revision** 29.3.2017

**Bibliography**
© Georg Thieme Verlag KG Stuttgart · New York
ISSN 2364-3722

**Corresponding author**
Yosuke Tsuji, Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan
Fax: +81-3-5800-9522
ytsuji-tyky@umin.ac.jp

**Abstract**

**Background and study aims** Endoscopic devices with injection function have been reported to decrease endoscopic submucosal dissection (ESD) operation times for experts, but the efficacy of these devices for inexperienced endoscopists is unclear. The aim of this study was to evaluate the feasibility of ESD using a novel ESD knife (DN-D2718B).

**Patients and methods** This is a single-center prospective pilot clinical feasibility study. Patients diagnosed with superficial gastrointestinal neoplasms were enrolled. A pre-specified group of ESD trainees with ESD experience on a porcine gastric model and fewer than 30 cases of ESD in their selected fields performed ESD under expert supervision, using the DN-D2718B. En bloc resection rates, R0 resection rates, procedure times, and incidence of intra-operative/post-operative adverse events were assessed.

**Results** Between June 2015 and January 2016, 13 esophageal, 27 gastric, and 14 colorectal ESD cases were performed per-protocol with mean resection speeds of 10.2, 12.0, and 15.5 mm²/min, respectively. There were no intra-operative/post-operative complications.

**Conclusion** ESD with this novel knife is feasible even when performed by non-experts.
Patients and methods

Endosurgical device DN-D2718A/B

The endosurgical device (DN-D2718B; HOYA Corporation, Pentax, Tokyo, Japan) is a needle-type device 2.0 mm in length, with injection function, designed for uniform use in all gastrointestinal organs (Fig. 1). Its unique characteristic is the 0.8-mm metal disk, which enables effective incision of the mucous layer and stabilizes the device during dissection. When retracted, electrical current spreads to the surrounding metal sheath, 1.8 mm in diameter, enabling effective hemostasis over a wide area. The wide injection shaft enables an effective elevation effect without the need for increasing injection pressure (Supplementary Video).

Optimum electrocautery settings in humans

A team of expert endoscopists, each with experience of over 100 cases of gastrointestinal ESD, performed preliminary ESD on 10 patients to determine optimum settings with a high-frequency generator VIO 300 D (ERBE Elektromedizin GmbH, Tübingen, Germany). Settings with Soft Coag, Swift Coag, Forced Coag, and Endocut were each tested for incision, dissection and hemostasis. Optimum electrocautery settings for esophageal and colorectal ESD were unanimously determined to be Endocut I (Effect 2, Duration 2, Interval 2) for incision and dissection, and Forced Coag (Effect 3, 30 W) for hemostasis. Similarly, optimum settings for gastric ESD were determined to be Endocut I (Effect 3, Duration 3, Interval 3) and Forced Coag (Effect 3, 30 W).

Pilot prospective clinical feasibility study

This pilot prospective clinical feasibility study was begun after approval from the research ethics committee in our institution, and trial registration (UMIN 000017575) in May 2015. Patients referred to our institute with a diagnosis of superficial gastrointestinal neoplasms were enrolled. Written forms of informed consent were obtained from all patients.

ESD trainees

Two trainees each were selected for evaluation of esophageal, gastric, and colorectal ESD. All trainees had over 1000 cases of gastroscopy experience [7, 8], and ESD experience of 1 porcine gastric model. The selected trainees for gastric ESD had experience of 25, 26 gastric ESD each, while trainees for esophageal and colorectal ESD had attained competency in gastric ESD.

![Image](57x548) **Fig. 1** Endosurgical device DN-D2718B. a When the knife is extended, the disk enables effective incision and stability during dissection. b When the tip is retracted, the entire metal surface enables coagulation. c Effective injection can be achieved with this device.

![Image](57x26) **Fig. 2** Flow diagram of the study patients.

<table>
<thead>
<tr>
<th></th>
<th>Esophageal cases meeting inclusion criteria and enrolled</th>
<th>Gastric cases meeting inclusion criteria and enrolled</th>
<th>Colorectal cases meeting inclusion criteria and enrolled</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>13 patients, 15 lesions</td>
<td>24 patients, 27 lesions</td>
<td>15 patients, 15 lesions</td>
</tr>
<tr>
<td>Refused entry</td>
<td>0 patients</td>
<td>0 patients</td>
<td>0 patients</td>
</tr>
<tr>
<td></td>
<td>2 patients, 2 lesions</td>
<td>0 patient, 0 lesion</td>
<td>1 patient, 1 lesion</td>
</tr>
<tr>
<td>Per-protocol treatment</td>
<td>11 patients, 13 lesions</td>
<td>24 patients, 27 lesions</td>
<td>14 patients, 14 lesions</td>
</tr>
</tbody>
</table>

Enrollment period: 2015.6 – 2016.1
after over 30 cases, but had no experience in their specified field.

**ESD procedure**

All ESD procedures were performed under oral supervision by experts with over 6 years of ESD training. An expert took over only when a trainee could not accomplish ESD, due to inability to continue the procedure as judged by the expert or due to complications [7, 8]. The selected trainees performed ESD as previously described [9]. In brief, the lesion margin was marked using the DN-D2718B with Forced Coag. Initial submucosal injection before incision was performed using a two-fold diluted solution of 0.4% hyaluronic acid (Mucoup; Johnson and Johnson K.K., Tokyo, Japan), followed by incision and dissection with the DN-D2718B. Injections of normal saline with the device were repeated as required during the procedure, followed immediately by dissection of the elevated area. In cases of esophageal ESD, polyglycolic acid sheets and fibrin glue were prophylactically used.

---

**Table 1** Results of ESD training with DN-D2718B.

<table>
<thead>
<tr>
<th>Trainee</th>
<th>Esophagus</th>
<th>Stomach</th>
<th>Colon</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>B</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>C</td>
<td>26</td>
<td>25</td>
<td>0</td>
</tr>
<tr>
<td>D</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>E</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>F</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
</tr>
</tbody>
</table>

**Results of ESD with DN-D2718B**

- **ESD in specified field (cases)**
  - Trainee A: 10
  - Trainee B: 3
  - Trainee C: 13
  - Trainee D: 14
  - Trainee E: 9
  - Trainee F: 5

**Patient Background**

- **Gender, male/female**
  - Trainee A: 10/0
  - Trainee B: 3/0
  - Trainee C: 9/4
  - Trainee D: 12/2
  - Trainee E: 4/5
  - Trainee F: 2/3

- **Age at ESD, mean ± SD, years**
  - Trainee A: 70.0 ± 6.0
  - Trainee B: 77.3 ± 10.0
  - Trainee C: 70.6 ± 9.0
  - Trainee D: 69.5 ± 6.9
  - Trainee E: 69.2 ± 12.1
  - Trainee F: 75.8 ± 11.7

**Tumor Background**

- **Tumor depth (M/SM1/SM2)**
  - Trainee A: 10/0/0
  - Trainee B: 3/0/0
  - Trainee C: 12/0/1
  - Trainee D: 13/0/1
  - Trainee E: 7/1/1
  - Trainee F: 5/0/0

- **Tumor maximum length, mean ± SD, mm**
  - Trainee A: 24.8 ± 15.4
  - Trainee B: 30.0 ± 13.1
  - Trainee C: 16.3 ± 8.9
  - Trainee D: 13.2 ± 8.5
  - Trainee E: 32.6 ± 11.2
  - Trainee F: 23.8 ± 19.4

- **Specimen maximum length, mean ± SD, mm**
  - Trainee A: 33.0 ± 13.8
  - Trainee B: 43.3 ± 33.3
  - Trainee C: 42.1 ± 9.4
  - Trainee D: 39.2 ± 12.8
  - Trainee E: 38.4 ± 9.0
  - Trainee F: 31.5 ± 15.8

- **Specimen size, mean ± SD, mm²**
  - Trainee A: 672.6 ± 465.7
  - Trainee B: 1204.2 ± 131.7
  - Trainee C: 1183.6 ± 593.0
  - Trainee D: 1031.9 ± 588.3
  - Trainee E: 1226.2 ± 451.2
  - Trainee F: 932.5 ± 857.6

**Results of ESD**

- **Self-completion, n/total (%)**
  - Trainee A: 10/10 (100)
  - Trainee B: 3/3 (100)
  - Trainee C: 10/13 (76.9)
  - Trainee D: 13/14 (92.9)
  - Trainee E: 9/9 (100)
  - Trainee F: 5/5 (100)

- **Resection time, mean ± SD, min**
  - Trainee A: 69.8 ± 43.1
  - Trainee B: 84.7 ± 43.6
  - Trainee C: 122.9 ± 65.2
  - Trainee D: 113.8 ± 61.5
  - Trainee E: 73.7 ± 34.3
  - Trainee F: 75.5 ± 26.3

- **Overall resection speed, mean ± SD, mm²/min**
  - Trainee A: 9.4 ± 3.9
  - Trainee B: 13.4 ± 4.6
  - Trainee C: 11.1 ± 7.2
  - Trainee D: 12.2 ± 5.9
  - Trainee E: 16.7 ± 6.6
  - Trainee F: 15.6 ± 9.1

- **En bloc resection rate, n/total (%)**
  - Trainee A: 10/10 (100)
  - Trainee B: 3/3 (100)
  - Trainee C: 13/13 (100)
  - Trainee D: 14/14 (100)
  - Trainee E: 9/9 (100)
  - Trainee F: 5/5 (100)

- **R0 resection rate, n/total (%)**
  - Trainee A: 7/10 (70.0)
  - Trainee B: 2/3 (66.7)
  - Trainee C: 13/13 (100)
  - Trainee D: 14/14 (100)
  - Trainee E: 6/9 (66.7)
  - Trainee F: 5/5 (100)

**Adverse events**

- **Incidence of intraoperative adverse events, n/total (%)**
  - Trainee A: 0/10 (0)
  - Trainee B: 0/3 (0)
  - Trainee C: 0/13 (0)
  - Trainee D: 0/14 (0)
  - Trainee E: 0/9 (0)
  - Trainee F: 0/5 (0)

- **Incidence of postoperative adverse events, n/total (%)**
  - Trainee A: 2/10 (20.0)
  - Trainee B: 1/3 (33.3)
  - Trainee C: 0/13 (0)
  - Trainee D: 2/14 (14.3)
  - Trainee E: 0/9 (0)
  - Trainee F: 0/5 (0)

ESD, endoscopic submucosal dissection; M, mucosal, SM, submucosal
* All postoperative adverse events after esophageal ESD were stricture, and after gastric ESD were delayed hemorrhage.
cally administered when lesions extended to over half the circumference of the esophagus [10]. In cases where stricture could not be prevented, balloon dilation was performed as required. Cases in which concurrent use of other ESD devices was required were predetermined to be excluded from analysis.

**Study endpoints**

Endpoints were set to assess the efficacy of the device. Procedure time, resection speed, en bloc resection rate, R0 resection rate, incidence of intra-operative AEs and postoperative AEs were assessed. R0 resection was defined as en bloc resection with histologically confirmed tumor-free horizontal and vertical margins. Perforation was defined as an endoscopically confirmed defect in the serosa, or free air detected by abdominal X-ray or CT. Intra-operative hemorrhage was defined as a decrease in hemoglobin of > 2 g/dL the day after ESD.

**Sample size**

As a pilot clinical study, 50 cases of ESD were set as the target for analysis. Assuming that all patients would have a single lesion, and with a conservative estimate that approximately 5% of patients would not be able to complete per-protocol treatment and therefore be excluded, the sample size was predetermined to be 52 patients.

**Results**

**Pilot prospective clinical feasibility study**

Between June 2015 and January 2016, a total of 52 patients composed of 13 with esophageal, 24 with gastric, and 15 with colorectal neoplasms were enrolled in this study (see Fig. 2 for details). After exclusion of cases as predetermined, a total of 49 patients and 54 cases of ESD were analyzed (Table 1).

En bloc resection was achieved in all cases. R0 resection rates were 69.2%, 100%, and 78.6%, while resection speeds were 10.2 ± 4.5, 12.0 ± 6.7, 15.5 ± 7.3 mm²/min for esophageal, gastric and colorectal ESD, respectively.

There were no intraoperative AEs. Postoperative AEs comprised 3 cases (23.1%) of postoperative stricture after esophageal ESD and 2 cases (7.4%) of delayed hemorrhage after gastric ESD.

**Discussion**

While the feasibility of use of novel ESD devices by experts has often been assessed [11, 12], feasibility of use by non-experts, while difficult to demonstrate, may be more clinically important. Through this first pilot prospective clinical feasibility study, we have demonstrated that ESD with the DN-D2718B is effective even in the hands of non-experts.

Procedure times and resection speeds with this device were comparable to or better than previous reports on ESD [13–15]. The R0 resection rate for esophageal and colorectal ESD, although comparable to or higher than previous reports [13–15], were lower than for gastric ESD. Histological evaluation of the resected specimens demonstrated a wide area of coagulation near the edges of the ESD specimen. While a large disk enables effective incision and hemostasis, resection with a wider margin may be required for histological evaluation of R0 resection, and finding the best balance will be necessary in future devices.

There were several limitations to our study. First, cases requiring use of other devices were excluded from analysis, which may be a cause of bias. The ITknife nano (KD-612L; Olympus Co.) was used in all of these cases, in circumstances where it became difficult to approach the target with the endoscope during the procedure. However, these circumstances may have been avoided in the hands of experts. Second, this was a single-center non-randomized pilot study with only a limited number of endoscopists and patients.

**Conclusion**

Although further studies are required for confirmation of the results in this study, effective ESD with this novel knife seems to be feasible.

**Competing interests**

T.Y. and F.M. receive collaborative research funding from Pentax and honoraria from Olympus, CSL Behring, and GUNZE Medical.

**References**


